Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine PCIA Background Infusion vs Non-background and Sufentanil for Postoperative Analgesia after Laparoscopic Abdominal Tumor Surgery
ChiCTR2600123455Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tegileridine in abdominal mass, hepatic neoplasm and gastrointestinal stromal tumor (GIST) (3 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Postoperative NRS scores (rest and activity) and Postoperative patient satisfaction. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
abdominal masshepatic neoplasmgastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2600123455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123455.